disease-modifying therapies + taurine

Taurine is being investigated as an adjunctive therapy to standard disease-modifying treatments (DMTs) for the treatment of relapsing-remitting multiple sclerosis (RRMS). Developed by the Sichuan Academy of Medical Sciences, this combination therapy aims to enhance remyelination and neuroprotection. Taurine, a naturally occurring amino acid and endogenous metabolite, is thought to work by reversing metabolic pathway flux and increasing the availability of serine, a critical building block for glycosphingolipids that constitute the myelin sheath. The Phase 2 clinical trial (NCT07263607) evaluates the efficacy of oral taurine supplementation in reducing MRI lesions, decreasing relapse rates, and slowing disability progression in patients already receiving stable DMT therapy.

Other names

DMTs + taurineTaurine Treatment for Multiple Sclerosis